UNDERSTANDING ELAPRASE

What is ELAPRASE® (Idursulfase)?

ELAPRASE is a prescription medicine for patients with Hunter syndrome. ELAPRASE has been shown to improve walking ability in patients 5 yrs and older.

In patients 16 months to 5 yrs old, ELAPRASE did not show improvement in disease-related symptoms or long term clinical result; however, treatment with ELAPRASE has reduced spleen size similarly to patients 5 yrs and older.

It is not known if ELAPRASE is safe and effective in children under 16 months old.

IMPORTANT SAFETY INFORMATION

RISK OF SERIOUS ALLERGIC REACTIONS:

Some patients have experienced serious allergic reactions (including life-threatening anaphylactic reactions) during and up to 24 hours after treatment, regardless of how long they were taking ELAPRASE. Anaphylactic reactions are immediate and include breathing problems, low oxygen levels, low blood pressure, hives and/or swelling of the throat or tongue. If a patient (you or your child) has experienced an anaphylactic reaction, the patient may require an extended period of observation by the patient’s healthcare team. If you or your child has breathing problems, a fever, or a respiratory illness, you or your child may be at risk of life-threatening worsening of those conditions due to allergic reactions from ELAPRASE. Your healthcare team should be advised of those conditions before treatment with ELAPRASE because the information may affect the timing of ELAPRASE treatment.

For Patients and Caregivers

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
For more information, please visit www.ELAPRASE.com

Please see Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
Please see Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
INTRODUCTION

Living with Hunter syndrome (also known as mucopolysaccharidosis II or MPS II) can be challenging, and processing the transition onto a treatment that you may not have heard of before can be overwhelming. This brochure provides an introduction to ELAPRASE in order to help you understand how it works and what to expect.

For further advice and information, please speak to your doctor and visit www.ELAPRASE.com, where you can find a variety of resources designed to help you feel supported and informed throughout your treatment journey.

The information contained in this brochure is not intended to replace the care and advice you should receive from your doctor.

IMPORTANT SAFETY INFORMATION (CONTINUED)

You or your child should be closely watched during and after ELAPRASE treatment and you should confirm with your healthcare team in advance of treatment that it is prepared to manage serious allergic reactions, including anaphylactic reactions. Tell your healthcare team immediately if any signs of an allergic reaction happen. Those signs may include breathing problems, low blood pressure, rash, hives, itching, flushing, fever and/or headache.

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
WHAT IS ELAPRASE?

ELAPRASE is a prescription medicine for patients with Hunter syndrome.

ELAPRASE has been shown to improve walking ability in patients 5 years and older.

In patients 16 months to 5 years old, ELAPRASE did not show improvement in disease-related symptoms or long term clinical result; however, treatment with ELAPRASE has reduced spleen size similarly to patients 5 years and older.

It is not known if ELAPRASE is safe and effective in children under 16 months old.

ELAPRASE is a type of enzyme replacement therapy (ERT) intended for Hunter syndrome patients who are unable to produce enough of the iduronate-2-sulfatase enzyme themselves.

ELAPRASE is an “enzyme replacement therapy” because it is a formulation of the enzyme called iduronate-2-sulfatase that is missing or low in people with Hunter syndrome. ELAPRASE is a purified form of the iduronate-2-sulfatase enzyme produced by recombinant DNA technology in a human cell line.

ELAPRASE may affect individuals differently and each person’s experience with ELAPRASE will be unique.

For help with the terminology highlighted in blue throughout this brochure, please refer to the glossary on page 19.

IMPORTANT SAFETY INFORMATION (CONTINUED)

When serious allergic reactions happened during clinical trials, later ELAPRASE treatments were managed with allergy-controlling drugs before or during treatment, a slower rate of ELAPRASE treatment, and/or early discontinuation of treatment.

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
HOW DOES ELAPRASE WORK?

The active substance in ELAPRASE is an enzyme that breaks down glycosaminoglycans (GAGs) that build up inside people with Hunter syndrome, causing the signs and symptoms of the condition. For example, the buildup of GAGs within organs such as the liver and spleen results in enlarged organ size.

As outlined on the next page, ELAPRASE is intended to reduce the levels of GAGs in cells.

HOW IS ELAPRASE ADMINISTERED?

ELAPRASE is administered intravenously (by infusion into a vein) once a week or as prescribed by a qualified healthcare professional, with appropriate emergency medical support readily available.

Infusions typically last up to 3 hours, but patients may require longer infusion times if hypersensitivity reactions occur, and additional time for preparation and observation may be needed.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Children with serious genetic mutations may be at risk for allergic reactions, serious side effects and antibody development. In a clinical study of children 7 years and younger, patients with certain types of genetic mutations experienced a higher number of allergic reactions, serious side effects, and development of an immune response to treatment. This immune response may interfere with the effectiveness of ELAPRASE. Talk to your healthcare team about whether you or your child may be at risk.

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
Healthy cell vs. Hunter syndrome-affected cell

In a healthy cell, GAGs are broken down and remain at a healthy level. In the cells of a Hunter syndrome patient, GAGs accumulate in the lysosomes, causing cellular and organ damage. Lysosomes are compartments within a cell.

**Healthy cell**

- Normal levels of GAGs
- Sufficient levels of iduronate-2-sulfatase
- Lysosome

**Hunter syndrome-affected cell**

- Accumulation of GAGs
- Insufficient levels of iduronate-2-sulfatase

How ELAPRASE works

After administration, ELAPRASE is absorbed into the cells, where it is intended to act in place of the missing enzyme to break down GAGs.

**ELAPRASE-treated cell**

Illustration only. Not intended to imply clinical significance.

ELAPRASE is intended to reduce the levels of GAGs in tissues

**IMPORTANT SAFETY INFORMATION (CONTINUED)**

If you or your child has breathing problems, other respiratory illness, heart problems, or susceptibility to fluid overload, you or your child may be at higher risk of fluid overload during ELAPRASE treatment. Your healthcare team should be advised of those problems before treatment and you should confirm with your healthcare team in advance of treatment that it is appropriately trained to watch for signs of fluid overload and provide the necessary medical support. Patients at risk for fluid overload may require longer observation time.

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
ELAPRASE® (idursulfase) is a global brand with over 15 years of real-world experience.

1917
First cases of Hunter syndrome characterized, later also known as mucopolysaccharidosis type 2 (MPS II).

1972
Hunter corrective factor found, later known as iduronate-2-sulfatase (I2S), the enzyme deficient or malfunctioning in Hunter syndrome patients.

1990
Discovery of enzyme replacement therapy as a possible treatment for Hunter syndrome.

1990–2000
Development of idursulfase, a purified form of the human I2S enzyme produced by recombinant DNA technology in a continuous human cell line.

IMPORTANT SAFETY INFORMATION (CONTINUED)

What are possible side effects of ELAPRASE?
The most common side effects of ELAPRASE include:

- In patients aged 5 and older:
  - Headache
  - Itching
  - Muscle and bone pain
  - Hives
  - Diarrhea
  - Cough

- In patients aged 7 years or younger:
  - Fever
  - Rash
  - Vomiting
  - Hives

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
The most common side effects needing medical attention were allergic reactions, and included rash, hives, itching, flushing, fever, and headache. **Tell your healthcare team immediately if any signs of an allergic reaction happen.** These are not all the possible side effects of ELAPRASE.

Please see additional Important Safety Information on **pages 16-17** and **CLICK HERE** to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
At OnePath, we provide you with tailored support for your Takeda therapy

When you’re prescribed ELAPRASE (idursulfase), OnePath dedicated product support is here for you.

At OnePath, we see a person, not a patient. We know that living with Hunter syndrome looks different for everyone. We get to know you, understand who you are, and learn what’s most important to you – so we can focus on what you specifically need when it comes to your prescribed Takeda therapy.

After you join OnePath, you’ll be connected with a specialist who acts as your go-to person. They’ll address your questions and concerns and help determine next steps. They’ll get you the information you need or find the right person who can. Because our goal is to make your journey a little easier.

To download the OnePath Start Form, visit www.ELAPRASE.com/getting-started-support/onopath

IMPORTANT SAFETY INFORMATION (CONTINUED)

RISK OF SERIOUS ALLERGIC REACTIONS:

Some patients have experienced serious allergic reactions (including life-threatening anaphylactic reactions) during and up to 24 hours after treatment, regardless of how long they were taking ELAPRASE. Anaphylactic reactions are immediate and include breathing problems, low oxygen levels, low blood pressure, hives and/or swelling of the throat or tongue. If a patient (you or your child) has experienced an anaphylactic reaction, the patient may require an extended period of observation by the patient’s healthcare team. If you or your child has breathing problems, a fever, or a respiratory illness, you or your child may be at risk of life-threatening worsening of those conditions due to allergic reactions from ELAPRASE. Your healthcare team should be advised of those conditions before treatment with ELAPRASE because the information may affect the timing of ELAPRASE treatment.
**How Can I Enroll in OnePath?**

1. Fill out the OnePath Start Form with your doctor.
2. Your doctor will send the Start Form to OnePath, who will take it from there.
3. After enrolling in OnePath, you’ll be connected with a Patient Support Manager who will act as your go-to person.

**Have questions?** Call OnePath at 1-866-888-0660, Monday through Friday, 8:30 am to 8:00 pm ET.

If English is not your preferred language, let us know. We can communicate with you over the phone using a translation service.
Here are some frequently asked questions:

**What is Hunter syndrome?**

Hunter syndrome is a genetic disorder that results in a lack of a specific enzyme, iduronate-2-sulfatase. This enzyme is needed to break down substances in the body called glycosaminoglycans (GAGs). Since patients with Hunter syndrome cannot break these substances down, the GAGs gradually build up in most of the organs in the body and can damage them. This causes a range of disease-related signs and symptoms, including diminished lung function and decreased walking ability. Ask your doctor about where to find more information about Hunter syndrome.

**What is ELAPRASE?**

ELAPRASE is a prescription medicine for patients with Hunter syndrome. ELAPRASE has been shown to improve walking ability in patients 5 years and older. In patients 16 months to 5 years old, ELAPRASE did not show improvement in disease-related symptoms or long term clinical result; however, treatment with ELAPRASE has reduced spleen size similarly to patients 5 years and older. It is not known if ELAPRASE is safe and effective in children under 16 months old.

It is a type of enzyme replacement therapy intended for Hunter syndrome patients who are unable to produce enough of the iduronate-2-sulfatase enzyme themselves.

**IMPORTANT SAFETY INFORMATION (CONTINUED)**

You or your child should be closely watched during and after ELAPRASE treatment and you should confirm with your healthcare team in advance of treatment that it is prepared to manage serious allergic reactions, including anaphylactic reactions. **Tell your healthcare team immediately if any signs of an allergic reaction happen.** Those signs may include breathing problems, low blood pressure, rash, hives, itching, flushing, fever and/or headache.

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
Why does the ELAPRASE prescribing information say that “In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long-term clinical outcome”?

A clinical trial, including patients aged 5 years and older, evaluated walking capacity and lung function, which are considered to be disease-related symptoms, and a 2-year extension study was carried out to gather longer-term data. These symptoms were not evaluated in the trial that included patients aged 16 months to 7 years.

To learn more about ELAPRASE clinical trials, visit www.ELAPRASE.com/what-is-elaprase/clinical-trials

Why does the prescribing information say that “The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age”?  

The clinical trials that studied ELAPRASE only included patients aged 16 months and older.

Is ELAPRASE a new medication?

No, ELAPRASE has been FDA-approved for use in the U.S. since 2006, and is also approved in 77 other countries after receiving respective marketing authorizations. Indication and risk information may vary by country.

When serious allergic reactions happened during clinical trials, later ELAPRASE treatments were managed with allergy-controlling drugs before or during treatment, a slower rate of ELAPRASE treatment, and/or early discontinuation of treatment.

Please see additional Important Safety Information on pages 16-17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
FREQUENTLY ASKED QUESTIONS (CONTINUED)

How is treatment with ELAPRASE administered?

ELAPRASE is administered intravenously (by infusion into a vein) once a week by a trained healthcare professional.

For more information on how ELAPRASE is administered and dosed, refer to the ELAPRASE Infusions: What to Expect guide, which can be provided by your doctor or downloaded from www.ELAPRASE.com/resources

What are the side effects of ELAPRASE?

Allergic reactions, including life-threatening anaphylaxis, have occurred in some patients treated with ELAPRASE. Anaphylactic reactions include breathing problems, low oxygen levels, low blood pressure, hives, and/or swelling of the throat or tongue. Inform your healthcare provider immediately if you notice any of these symptoms beginning.

In clinical trials, the most common side effects, occurring in at least three patients aged 5 years or older, were headache, itching, muscle and bone pain, hives, diarrhea, and cough. Among patients aged 7 years or younger, the most common adverse reactions occurring in at least three patients were fever, rash, vomiting, and hives.

How can I find out if I can switch to home infusions?

Please speak to your doctor about home infusions. Patients who tolerate ELAPRASE infusions well may be able to receive infusions at home under the supervision of a healthcare professional.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Children with serious genetic mutations may be at risk for allergic reactions, serious side effects and antibody development. In a clinical study of children 7 years and younger, patients with certain types of genetic mutations experienced a higher number of allergic reactions, serious side effects, and development of an immune response to treatment. This immune response may interfere with the effectiveness of ELAPRASE. Talk to your healthcare team about whether you or your child may be at risk.

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
Should the ELAPRASE infusion be postponed if you are unwell?

Inform your healthcare team of any illness prior to the ELAPRASE infusion, and they will decide whether to delay the ELAPRASE infusion. If you or your child has breathing problems, a fever, or a respiratory illness, you or your child may be at risk of life-threatening worsening of those conditions due to allergic reactions to ELAPRASE. Your healthcare team should be advised of those conditions before treatment with ELAPRASE because the information may affect the timing of ELAPRASE treatment.

Please refer to the Important Safety Information on pages 16–17 and CLICK HERE to see the Full Prescribing Information.

What is OnePath and how can it help me?

OnePath is a free-of-charge product support service provided by Takeda to eligible patients with Hunter syndrome receiving ELAPRASE. The OnePath patient support team is committed to providing personalized, one-on-one product support services to help you and your family access the support and treatment you need.

OnePath can help you set up your ELAPRASE therapy and help you and your family coordinate your care.

For more information about OnePath, visit www.OnePath.com

IMPORTANT SAFETY INFORMATION (CONTINUED)

If you or your child has breathing problems, other respiratory illness, heart problems, or susceptibility to fluid overload, you or your child may be at higher risk of fluid overload during ELAPRASE treatment. Your healthcare team should be advised of those problems before treatment and you should confirm with your healthcare team in advance of treatment that it is appropriately trained to watch for signs of fluid overload and provide the necessary medical support. Patients at risk for fluid overload may require longer observation time.

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
What is ELAPRASE® (Idursulfase)?

ELAPRASE is a prescription medicine for patients with Hunter syndrome. ELAPRASE has been shown to improve walking ability in patients 5 yrs and older. In patients 16 months to 5 yrs old, ELAPRASE did not show improvement in disease-related symptoms or long term clinical result; however, treatment with ELAPRASE has reduced spleen size similarly to patients 5 yrs and older. It is not known if ELAPRASE is safe and effective in children under 16 months old.

Important Safety Information

**RISK OF SERIOUS ALLERGIC REACTIONS:**

Some patients have experienced serious allergic reactions (including life-threatening anaphylactic reactions) during and up to 24 hours after treatment, regardless of how long they were taking ELAPRASE. Anaphylactic reactions are immediate and include breathing problems, low oxygen levels, low blood pressure, hives and/or swelling of the throat or tongue. If a patient (you or your child) has experienced an anaphylactic reaction, the patient may require an extended period of observation by the patient’s healthcare team. If you or your child has breathing problems, a fever, or a respiratory illness, you or your child may be at risk of life-threatening worsening of those conditions due to allergic reactions from ELAPRASE. Your healthcare team should be advised of those conditions before treatment with ELAPRASE because the information may affect the timing of ELAPRASE treatment.

You or your child should be closely watched during and after ELAPRASE treatment and you should confirm with your healthcare team in advance of treatment that it is prepared to manage serious allergic reactions, including anaphylactic reactions. **Tell your healthcare team immediately if any signs of an allergic reaction happen.** Those signs may include breathing problems, low blood pressure, rash, hives, itching, flushing, fever and/or headache.

When serious allergic reactions happened during clinical trials, later ELAPRASE treatments were managed with allergy-controlling drugs before or during treatment, a slower rate of ELAPRASE treatment, and/or early discontinuation of treatment.

Please see additional Important Safety Information on page 17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
Important Safety Information (continued)

Children with serious genetic mutations may be at risk for allergic reactions, serious side effects and antibody development. In a clinical study of children 7 years and younger, patients with certain types of genetic mutations experienced a higher number of allergic reactions, serious side effects, and development of an immune response to treatment. This immune response may interfere with the effectiveness of ELAPRASE. Talk to your healthcare team about whether you or your child may be at risk.

If you or your child has breathing problems, other respiratory illness, heart problems, or susceptibility to fluid overload, you or your child may be at higher risk of fluid overload during ELAPRASE treatment. Your healthcare team should be advised of those problems before treatment and you should confirm with your healthcare team in advance of treatment that it is appropriately trained to watch for signs of fluid overload and provide the necessary medical support. Patients at risk for fluid overload may require longer observation time.

What are possible side effects of ELAPRASE?

The most common side effects of ELAPRASE include:

- In patients aged 5 and older:
  - Headache
  - Itching
  - Muscle and bone pain
  - Hives
  - Diarrhea
  - Cough

- In patients aged 7 years or younger:
  - Fever
  - Rash
  - Vomiting
  - Hives

The most common side effects needing medical attention were allergic reactions, and included rash, hives, itching, flushing, fever, and headache. Tell your healthcare team immediately if any signs of an allergic reaction happen. These are not all the possible side effects of ELAPRASE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
WHAT OTHER RESOURCES ARE AVAILABLE TO ME?

Websites

ELAPRASE website (www.ELAPRASE.com)
More information about ELAPRASE and its clinical trials, as well as access to many other resources.

MPS Society (www.mpssociety.org)
Hunter syndrome is one of a group of lysosomal storage diseases and this website has resources, support, and ways to connect to other patients.

ELAPRASE guides

ELAPRASE Infusions: What to Expect
Practical advice on preparing for your infusions.

ELAPRASE Reimbursement Guide
Guidance on ELAPRASE coverage and the reimbursement process.

Understanding ELAPRASE: Doctor Discussions
A booklet for you to take to your doctor appointments, designed to help you take notes and ask any questions you might have.

ELAPRASE emails

Stay up to date with ELAPRASE news and updates by signing up to receive occasional emails: www.ELAPRASE.com/stay-updated

These resources are not intended to replace the care and advice you should receive from your doctor.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Children with serious genetic mutations may be at risk for allergic reactions, serious side effects and antibody development. In a clinical study of children 7 years and younger, patients with certain types of genetic mutations experienced a higher number of allergic reactions, serious side effects, and development of an immune response to treatment. This immune response may interfere with the effectiveness of ELAPRASE. Talk to your healthcare team about whether you or your child may be at risk.

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
Enzyme replacement therapy (ERT) – Treatment that works by replacing the missing or deficient enzyme in a disease. ELAPRASE is an ERT and is intended to replace the iduronate-2-sulfatase enzyme in patients with Hunter syndrome.

Glycosaminoglycans (pronounced gli-ko-sah-mee-no-gli-cans) (GAGs) – Long sugar molecules that are a component of connective tissue in the body. GAGs may also be referred to as mucopolysaccharides and build up in patients with Hunter syndrome.

Hypersensitivity – Occurs when a person’s body has an undesirable reaction to a substance. In regard to ELAPRASE, allergic reactions can occur upon administration and up to 24 hours after treatment so it is important for your doctor to be prepared to handle this if hypersensitivity does occur in a patient. Please refer to the Important Safety Information on pages 16–17 and CLICK HERE to see the Full Prescribing Information.

Iduronate-2-sulfatase (I2S) – This is the name of the enzyme that is missing or deficient in people with Hunter syndrome. ELAPRASE contains a purified form of this enzyme, which is intended to break down the long complex sugar molecules.

Infusion – A therapy that requires administration of a drug through a needle or catheter. ELAPRASE is administered by an infusion so you will go to an infusion center.

Mucopolysaccharidosis (pronounced mew-ko-pol-ee-sak-ah-ride-o-sis) (MPS) II – An alternative name for Hunter syndrome. Hunter syndrome is one type of a collection of diseases called mucopolysaccharidoses, which all involve the accumulation of long sugar molecules that cannot be broken down.

Recombinant DNA technology – Technology that is used to combine different bits of genetic material that can then code for a new protein. ELAPRASE is made up of an enzyme, which is a type of protein, that is created using this method.

IMPORTANT SAFETY INFORMATION (CONTINUED)

If you or your child has breathing problems, other respiratory illness, heart problems, or susceptibility to fluid overload, you or your child may be at higher risk of fluid overload during ELAPRASE treatment. Your healthcare team should be advised of those problems before treatment and you should confirm with your healthcare team in advance of treatment that it is appropriately trained to watch for signs of fluid overload and provide the necessary medical support. Patients at risk for fluid overload may require longer observation time.

Please see additional Important Safety Information on pages 16–17 and CLICK HERE to see accompanying Full Prescribing Information, including Boxed WARNING for Risk of Anaphylaxis.
What is ELAPRASE® (Idursulfase)?

ELAPRASE is a prescription medicine for patients with Hunter syndrome.

ELAPRASE has been shown to improve walking ability in patients 5 yrs and older.

In patients 16 months to 5 yrs old, ELAPRASE did not show improvement in disease-related symptoms or long term clinical result; however, treatment with ELAPRASE has reduced spleen size similarly to patients 5 yrs and older.

It is not known if ELAPRASE is safe and effective in children under 16 months old.

IMPORTANT SAFETY INFORMATION

RISK OF SERIOUS ALLERGIC REACTIONS:

Some patients have experienced serious allergic reactions (including life-threatening anaphylactic reactions) during and up to 24 hours after treatment, regardless of how long they were taking ELAPRASE. Anaphylactic reactions are immediate and include breathing problems, low oxygen levels, low blood pressure, hives and/or swelling of the throat or tongue. If a patient (you or your child) has experienced an anaphylactic reaction, the patient may require an extended period of observation by the patient’s healthcare team. If you or your child has breathing problems, a fever, or a respiratory illness, you or your child may be at risk of life-threatening worsening of those conditions due to allergic reactions from ELAPRASE. Your healthcare team should be advised of those conditions before treatment with ELAPRASE because the information may affect the timing of ELAPRASE treatment.